GLPwatch
Papers (12034)
Page 175 of 201, ranked by citation count.
- [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
- The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.
- Calculating cost per event avoided using a composite number needed to treat.
- Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study.
- Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.
- Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?
- Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
- Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.
- [Nephrology : what's new in 2025].
- Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.
- No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.
- Impact of Exendin-4 on the Differentiation and Function of Transplanted Porcine Neonatal Pancreatic Cell Clusters in Diabetic Nude Mice.
- Semaglutide Use Is Associated With Decreased Length of Stay and Hospital Costs in Patients Undergoing Anterior Lumbar Interbody Fusion: A Retrospective Cohort Study.
- Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice.
- Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.
- Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.
- Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.
- Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs).
- A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.
- Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"
- A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.
- Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.
- Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression.
- Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.
- Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature.
- [Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system].
- After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
- [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
- Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
- In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
- Starvation ketosis following self-administered tirzepatide obtained via online services in a young woman later diagnosed with anorexia nervosa: a case report.
- Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.
- Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.
- Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
- Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
- The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac Catheterization.
- Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
- Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
- Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.
- Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
- Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.
- A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa.
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
- Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1.
- Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
- Liraglutide alleviates postoperative cognitive impairment via NRF2/NLRP3 signal pathway in aged mice.
- [New outcome studies with injectable semaglutide in different at risk populations].
- Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.
- Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.
- [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
- Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.
- Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.
- Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.
- Tirzepatide Causes Weight Loss and Improves Sleep Apnea Symptoms.
- Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study.